ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
This is a Phase 1/2, multi-center, open-label study of CPI-1205 + ipilimumab in patients with histologically or cytologically confirmed advanced solid tumors. This study is designed to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of CPI-1205 + ipilimumab in patients with advanced solid tumors. Patients in Phase 2 will be treated at the RP2D of CPI-1205 + ipilimumab. This study was stopped prior to proceeding to Phase 2; no patients were enrolled in Phase 2.
Epistemonikos ID: 8d44540fc0fb3e8d14821a0adea913d14136136a
First added on: May 21, 2024